EyePoint Pharmaceuticals

Press Releases

Feb 12, 2009
Dr. Paul Ashton appointed President and CEO
Feb 03, 2009
Dr. Paul Ashton appointed President and CEO Watertown, MA – February 3, 2009 – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company today announced that Paul Ashton, Ph.D. has been named President and Chief Executive Officer. Dr. David J.
pSivida New Evaluation for Cardiovascular Drug Delivery
Dec 17, 2008
pSivida New Evaluation for Cardiovascular Drug Delivery Watertown, MA (December 16, 2008) - Drug delivery company pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3) has entered into a technology evaluation agreement to evaluate cardiovascular delivery of drugs using pSivida's drug delivery
pSivida new clinical trial for drug delivery device in AMD
Dec 12, 2008
pSivida new clinical trial for drug delivery device in AMD Watertown, MA (December 12, 2008) – Drug delivery company pSivida Corp (NASDAQ: PSDV, ASX: PVA, FF: PV3) today announced that a clinical trial has begun using its MedidurTM delivery technology to treat a form of dry-Age related Macular
pSivida’s BrachySil pancreatic cancer treatment featured on the BBC
Dec 03, 2008
pSivida’s BrachySil pancreatic cancer treatment featured on the BBC Watertown, MA (December 3, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, today announced that its lead oncology product, BrachySilTM for the treatment of pancreatic cancer, has been featured in a
Nov 21, 2008
Nov 12, 2008
pSivida Corp. September Qtr 2008 Earnings Report
Oct 31, 2008
pSivida Corp. September Qtr 2008 Earnings Report WATERTOWN, MA – October 31, 2008 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, today announced that its financial results for the first quarter ended September 30, 2008 will be filed with the SEC and the ASX on or
Results from the six-month interim readout of the Human PK Iluvien Study
Oct 02, 2008
Results from the six-month interim readout of the Human PK Iluvien Study Boston, MA – Drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), together with its licensing and development partner, Alimera Sciences have today reported the interim six-month safety and efficacy results
DSMB Supports continuation of the Phase III clinical trial of Iluvien for the treatment of DME
Sep 26, 2008
DSMB Supports continuation of the Phase III clinical trial of Iluvien for the treatment of DME Boston, MA (September 26, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3) today announced that after completing its review of safety and efficacy data currently
pSivida Quarterly Cash Flow – June 30, 2008 Commentary and Highlights
Jul 31, 2008
pSivida Quarterly Cash Flow – June 30, 2008 Commentary and Highlights pSivida Quarterly Highlights - Reincorporation in the US Completed - Interim results from Medidur for DME Study - Commencement of new Medidur AMD Trial - Commencement of BrachySil Pancreatic Cancer Dose Ranging Clinical Trial
pSivida New Board Appointments
Jul 14, 2008
pSivida New Board Appointments Boston, MA (July 14, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company headquartered in Watertown, MA, is pleased to announce the appointment to their Board of Directors of Peter G. Savas and Paul A.
pSivida Corp: BrachySil™ Phase IIb Pancreatic Cancer Trials Commence
Jul 07, 2008
pSivida Corp: BrachySil™ Phase IIb Pancreatic Cancer Trials Commence Boston, MA. and Perth, Australia (July 7, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a global drug delivery company is pleased to announce that a Phase IIb clinical trial has commenced with BrachySil™ (P32
pSivida MD to ring NASDAQ Closing Bell
Jul 01, 2008
pSivida MD to ring NASDAQ Closing Bell Boston, MA and Perth, Australia (June 30, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today announced that Dr. Paul Ashton, Managing Director, will ring the NASDAQ Stock Market Closing Bell on Tuesday, July 1, at 4
pSivida Interim results from the 3-month Human PK Medidur FA Study
Jun 27, 2008
pSivida Interim results from the 3-month Human PK Medidur FA Study Boston, MA and Perth, Australia (June 27, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today reported the interim three-month safety and efficacy results from the first human
Open Briefing Interview with Managing Director, Dr Paul Ashton - pSivida reincorporation in the US
Jun 20, 2008
Open Briefing Interview with Managing Director, Dr Paul Ashton - pSivida reincorporation in the US Date of lodgement: 20-Jun-2008 Title: Open Briefing®. pSivida. Reincorporation of pSivida to US Record of interview: corporatefile.com.au pSivida Ltd. (NASDAQ:PSDVV, ASX:PVA, FSE:PSI) has implemented
pSivida Scheme of Arrangement Implemented
Jun 19, 2008
pSivida Scheme of Arrangement Implemented Boston, MA and Perth, Australia (19 June 2008) - pSivida Corp. (ASX: PVA, NASDAQ: PSDVV, FSE: PSI) announces that the Scheme of Arrangement between pSivida Limited and its shareholders has today been implemented.
Jun 12, 2008
Jun 11, 2008
Jun 11, 2008
Displaying 301 - 320 of 343
EyePoint Pharmaceuticals